CSL Limited (CMXHF)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Mixed 2/5 metrics rated Sunny
What does CSL Limited do?
CSL Limited is an innovative biopharmaceutical company that develops, manufactures, and distributes life-saving therapies worldwide. With headquarters in Parkville, Australia, they specialize in plasma therapies for immunodeficiency and bleeding disorders, as well as non-plasma biotherapeutic products. They are constantly researching and developing new treatments, making them a global leader in healthcare. 💉🌍.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛈️ Weak | 5-year price performance |
| Profitability | ⛈️ Weak | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $120.44 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Returns have been below average recently — worth reviewing valuation carefully before investing. Sign up free to see the full Stockbruh valuation breakdown.
How the business works
CSL Limited is an innovative biopharmaceutical company that develops, manufactures, and distributes life-saving therapies worldwide. With headquarters in Parkville, Australia, they specialize in plasma therapies for immunodeficiency and bleeding disorders, as well as non-plasma biotherapeutic products. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — CSL Limited appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.